Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA warning letter

This article was originally published in The Tan Sheet

Executive Summary

Nature's Way Products should take prompt action to correct a number of violations identified during an FDA inspection of the company's Springville, Utah, facility in September, the agency says in a recent letter to the firm. The company was required to notify the agency in writing of specific steps it would take to correct the violations, including the fact its red yeast rice product promoted as a dietary supplement was found to contain lovastatin, an ingredient in FDA-approved drugs used to treat patients with primary hypercholesterolemia, FDA maintains. The product's labeling confirms its use as a drug, since it claims to "prevent, treat, or cure disease conditions or to affect the structure or function of the body," FDA adds. Additionally, the product is misbranded since it fails to bear adequate direction for its intended uses. "Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction," FDA adds. The agency issued similar warnings to other firms and announced a crackdown on adulterated red yeast rice products in August (1"The Tan Sheet" August 13, 2007, In Brief)...

You may also be interested in...



Adulturated red yeast rice

FDA threatens enforcement action against two firms selling red yeast rice supplements adulterated with lovastatin - the active ingredient in Merck's Rx cholesterol-lowering drug Mevacor. Consumers should not purchase or consume Swanson Healthcare Products' Red Yeast Rice and Red Yeast Rice/Policosonal Complex or Sunburst Biorganics' Cholestrix since FDA testing revealed the presence of the statin, which can cause harmful side-effects such as muscle weakness and kidney issues and may interact with other medications, FDA announces Aug. 9. The agency determined the adulterated supplements are unapproved new drugs, sent warning letters to the companies marketing the products and threatens to employ enforcement actions, such as seizure of illegal products and criminal prosecution if the companies fail to resolve the violations immediately, according to the warning letters. In January 2005, Source Naturals received a courtesy letter from FDA for the same problem (1"The Tan Sheet" Jan. 24, 2005, In Brief)...

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Torrent’s $245m Curatio Deal Gives Pole Position In Fast-Growing Cosmetic Dermatology

Torrent’s $245m acquisition of Curatio Healthcare has moved it up a rank to No.7 in the overall Indian pharmaceutical market apart from making it the market leader in cosmetic dermatology. While it’s a pricey deal, factors like growing prevalence of skin diseases and shift towards e-commerce bode well for future revenue growth in a nascent market

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel